-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
For decades, the antimalarial drug hydroxychloroquine (HCQ) has played an important role in the treatment of including inflammatory rheumatic diseases due to its immunomodulatory properties and overall favorable safety profi.
Data in recent years suggest that HCQ may have other beneficial effects beyond its ability to control disease activity
It has been investigated whether hydroxychloroquine treatment is associated with major adverse cardiovascular events (MACE) (myocardial infarction, ischemic stroke, or cardiovascular-related death) in patients with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE)
Is hydroxychloroquine treatment associated with major adverse cardiovascular events (MACE) (myocardial infarction, ischemic stroke, or cardiovascular-related death) in patients with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE)
METHODS: An observational cohort study including patients with a first diagnosis of CLE or SLE (1997 to 2017) was conducted according to the Danish National Regist.
method:
Number of events per 1000 person-years, duration of follow-up and incidence of HCQ users and non-users:
Number of events per 1000 person-years, duration of follow-up and incidence of HCQ users and non-users:
Results: Of the 4587 LE patients, 51% (n = 2343) received hydroxychloroquine during the study peri.
result:
Forest plots showing crude and adjusted hazard ratios for hydroxychloroquine users compared to non-users in patients with LE:
Forest plots showing crude and adjusted hazard ratios for hydroxychloroquine users compared to non-users in patients with LE:
Although there is no information on disease activity/severi.
But the findings suggest that the risk of cardiovascular events in LE patients can be reduced by using hydroxychloroqui.
The potential temporal association between hydroxychloroquine (HCQ) use and cardiovascular (CV) events in patients with SLE or RA was assessed
Methods: A nested case-control study was performed in an initial cohort of SLE and RA patients using an administrative health database that included the entire population of British Columbia, Cana.
method:
Results: 10,268 cases and 29,969 controls were identifi.
result:
Therefore, in this nested case-control study of patients with SLE and RA, a reduction in the overall risk of CV events, including reduction in VTE and a trend towards reduction in MI and stroke, was found associated with current use of HCQ
A reduction in the overall risk of CV events, including a reduction in VTE and a trend towards a reduction in MI and stroke, was found associated with current HCQ u.
references:
Jorge A, Lu N, Choi H, Esdaile JM, Lacaille D, Avina-Zubieta .
Jorge A, Lu N, Choi H, Esdaile JM, Lacaille D, Avina-Zubieta .
Haugaard JH, Dreyer L, Ottosen MB, Gislason G, Kofoed K, Egeberg.
leave a message here
